Laboratory for Advanced Medicine & Health

LAMH (Laboratory for Advanced Medicine & Health Group) is an innovative enterprise focused on AI-driven cancer early screening and diagnosis. It was co-founded by international business leaders, top scientists and authoritative doctors, with the concept of "making cancer screening earlier, more accurate, accessible and convenient". Since its establishment, LAMH has raised more than 1 billion RMB in financing. As a global leader in cancer early screening and diagnosis, LAMH cooperates with multiple top cancer centers, universities, and affiliated hospitals. It has published related research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and has established a full product pipeline for early screening and diagnosis of liver cancer, colorectal cancer, lung cancer, and pan-cancer. With the help of AI-driven technology, LAMH is committed to providing users with a full life-cycle service, combining genomics and clinical medicine theory.

LAMH, an independent entity in China, has its headquarters located in Guangzhou Pazhou Center Business District, a research and registration center in Beijing Economic and Technological Development Zone, Southern and Northern Medical Testing Laboratories (ICL) that meet PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang respectively, and an IVD GMP factory through NMPA assessment in Guangzhou Science City. Helio Genomics, an independent entity in the United States, is headquartered in Irvine, California, and has a central laboratory certified by CLIA and CAP in Indiana.


Making cancer screening earlier,

more accurate, accessible and convenient.


A technology-driven global leader

in early cancer detection.


Result-oriented, customer-centric,

and people-oriented.

Core Technology
A technology-driven global leader in early cancer detection.
The world's first large scale liver cancer early screening research results based on cfDNA methylation technology, pioneering the use of cfDNA methylation for early cancer screening.
LAMH research results show that methylation markers can be used effectively in the diagnosis and prognosis of breast, colorectal, liver and lung cancers.
CHALM-cell heterogeneity-adjusted methylation quantitative analysis method.
Research published in the Journal of the American Association for the Study of Liver Cancer has shown that the LAMH HelioLiver Test, a liver cancer early screening product, can accurately detect early stage liver cancer.
IvyGene® Liver
Hepatocellular carcinoma gene
methylation test
IvyGene®Liver Plus
Hepatocellular carcinoma gene
methylation test
lvyGene® PLUS
Early and accurate cancer screening
Core Team
Zeyue Zhang
Chairman / CEO
Zeyue Zhang
Chairman / CEO

Mr. Zeyue Zhang has a rich background in Business, clinical medicine and biotechnology in the gene industry; He has management experience in start-up companies, multinational enterprises, well-known private enterprises and state-owned enterprises. He has worked in well-known domestic gene companies such as BGI, BoA, Roche and Novartis, as well as the sales department of well-known multinational pharmaceutical companies.

Bachelor of Medicine, Southern Medical University;
Executive Master of Business Administration (EMBA) from China Europe International Business School (CEIBS).

Shu Li
Founder / Co-Chairman
Shu Li
Founder / Co-Chairman

Dr. Shu Li is a successful entrepreneur in the biomedical field. He served as senior vice president of Conexant Systems, vice president and general manager of Honeywell Commercial Spare Parts, and held senior management positions in Motorola and Intel. Dr. Li Shu is a member of the Advisory Board of the University of California, Irvine (Business School), and has also served as a faculty member at the University of Arizona. He holds 6 US and international patents.

Bachelor of Automatic Control from Huazhong University of Science and Technology;
Degree in Electrical Engineering from the University of Illinois at Urbana-Champaign;
PhD in Applied Science from Harvard University.

Company History
The world's earliest methylation technology company
Obtains UCSD's global first methylation cancer screening technology.
LAMH was officially established.
Granted PCT patent
Including methylation markers for solid tumors, colorectal cancer, lung cancer, leukemia, breast cancer, ovarian cancer, and liver cancer.
Granted Chinese patents
For methylation markers for diagnosing liver cancer and lung cancer, as well as methylation markers for cancer diagnosis.
Completed NMPA registration for liver cancer detection
Becoming the first company to pass China's liver cancer methylation detection IVD registration.
The first to launch China's NMPA liver cancer clinical trial
Receive a major project from the Ministry of Science and Technology of China
And jointly develop Chinese population-based liver cancer, colorectal cancer, and lung cancer screening standards and technical routes.
Completed NMPA liver cancer clinical trial and releases clinical trial data.
Completed product standardization for colorectal cancer early screening
multi-omics blood products by PCR laboratory acceptance.
Commercialization of liver cancer products officially launches.
LAMH launches commercialization of scale liver cancer LDT testing products
Pan-cancer early screening multi-omics blood products marker screening
and five-cancer early screening LDT products launched
Launches MR liver cancer recurrence monitoring project.
LAMH was recognized as the first batch of "National High-tech Enterprises" in 2022.
莱盟健康LAMH MR肝癌复发监测项目启动
Latest News
Cutting-edge cooperation
Stanford Medicine
Johns Hopkins
Harvard Medical School
Cleveland Clinic
UCI Rvine
Uc San Diego
Purdue University
University Of Arizona
U Health
Moffitt Cancer Center
Ochsner Health
Cedars Sinai
Listed in no particular order
《Nature Materials》
Researchers analyzed ctDNA methylation models of 1098 liver cancer patients and 835 normal individuals, and established integrated diagnostic models (AUC: 0.969) and comprehensive prognostic models with 10 and 8 methylation sites, respectively, which possess high sensitivity and specificity. These models were used for real-time tumor load detection, treatment response, recurrence monitoring and prognosis evaluation of liver cancer patients. Compared with AFP detection, the integrated diagnostic model has higher sensitivity and specificity in stages I, II, and III tumors, while AFP does not change much except in stages III and IV liver cancer.
Read more
Researchers used AI training on methylation data from TCGA and Chinese clinical samples in NGS technology, and screened out specific methylation models for four common cancers (breast cancer, colorectal cancer, liver cancer, and lung cancer). The verification results showed that the methylation model can detect the four types of cancer with an accuracy rate of over 95% in the Chinese population.
Read more
《Nature Communications》
The current methylation quantitative analysis method does not consider the heterogeneity of cells during sequencing, which may lead to weak correlation between methylation analysis results and gene expression data. The CHALM algorithm helps us better reveal the function of DNA methylation and its correlation with gene expression.
Read more
《Nature Materials》
HelioLiver Test is a blood test that combines cfDNA methylation patterns with tumor protein markers analysis. In a double-blind, multi-center clinical validation study of 122 liver cancer patients and 125 cirrhosis patients, HelioLiver Test had a sensitivity of 85% for detecting liver cancer, and 76% for early-stage (AJCC I and II) liver cancer, while the specificity was also up to 91%, which is significantly better than AFP and GALAD models.
Read more